Researchers from the Vanderbilt University School of Medicine Basic Sciences have uncovered the first example of activity-dependent development of hypothalamic neural circuitry. Although previous ...

FDA approval establishes setmelanotide as the first labeled option for acquired hypothalamic obesity, addressing a population ...

Researchers from the lab of Richard Simerly have uncovered the first example of activity-dependent development of hypothalamic neural circuitry. The work also suggests a novel role for the hunger ...

Scientists at Pennington Biomedical Research Center have gained greater clarity in the brain regions and neurons that control metabolism, body temperature and energy use. Featured in the February ...

Palatin Technologies Inc. has obtained U.S. orphan drug designation for PL-7737 for leptin receptor (LEPR) deficiency, including obesity caused by this condition.

REGN-4461 (mibavademab) is a monoclonal antibody targeting leptin receptor (LEP-R) under development by Regeneron Pharmaceuticals Inc. It acts as an allosteric agonist and does not compete with leptin ...

CRANBURY, N.J., March 25, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the ...

Obesity has become a global epidemic affecting diverse populations and leading to metabolic syndrome across different sexes and age groups. A significant aspect of obesity is the development of leptin ...

Metabolic dysfunction-associated fatty liver disease (MAFLD) has emerged as a predominant chronic liver condition globally, intricately linked with obesity, type 2 diabetes (T2DM), and metabolic ...

Add Yahoo as a preferred source to see more of our stories on Google. If you constantly feel hungry no matter how you try to manage your appetite, a hormonal imbalance known as leptin resistance could ...